NACD Announces 10 Finalists for the 2024 DE&I Awards
WASHINGTON, July 2, 2024 /PRNewswire/ -- The National Association of Corporate Directors (NACD) announced today the 10 finalists for its 2024 Diversity, Equity & Inclusion (DE&I) Awards. The NACD DE&
Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
Can the "miracle drug" of 100% preventing AIDS break the deadlock, but the stock price of Gilead (GILD.US) cannot be happy?
Can the 100% HIV prevention "miracle drug" become Gilead's next ace?
Gilead Sciences(GILD.US) Officer Sells US$137.26K in Common Stock
$Gilead Sciences(GILD.US)$ Officer Parsey Merdad sold 2,000 shares of common stock on Jul 1, 2024 at an average price of $68.63 for a total value of $137.26K.Source: Announcement What is statement of
Form 144 | Gilead Sciences(GILD.US) Officer Proposes to Sell 137.26K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Gilead Sciences(GILD.US)$ Officer MERDAD V PARSEY intends to sell 2,000 shares of its common stock on Jul 1, with a total market value of approximately $137.26K. Sou
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study
HOOKIPA Pharma (HOOK) said Monday the first person has been dosed in its phase 1b study of its investigational vaccine HB-500 for the treatment of HIV. The study will evaluate safety and tolerability,
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:GILD) with a Sector Perform and maintains $74 price target.
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 6.03% RBC Capital $74 → $74 Reiterates Sector Perform → Sector Perform 06/20/2024 14.63% Baird
Gilead Benefit Helps Employees Navigate Cancer Care
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resource
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
RBC Capital Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $74
RBC Capital analyst Brian Abrahams maintains $Gilead Sciences(GILD.US)$ with a hold rating, and maintains the target price at $74.According to TipRanks data, the analyst has a success rate of 48.6% an
Should You Hold Gilead Sciences (GILD)?
Gilead Sciences (GILD) Receives a Hold From RBC Capital
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
A Tech Reckoning Is Coming, Financial Pro Says. It's Time to Play Defense.
The Bahnsen Group's chief investment officer recommends taking the moment to buy stocks with a history of paying dividends in defensive sectors.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash
American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond
USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million...
Express News | Cellares: Kite, a Gilead Company, Will Evaluate Co's Automated Manufacturing Platform Cell Shuttle